These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 4551793)

  • 21. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N; Rada G
    Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Artifactual hypoglycaemia in a patient with scleroderma and Raynaud's phenomenon.
    Osman R; Erasmus E; Lahri S; Moosajee F
    S Afr Med J; 2021 Feb; 111(2):13202. PubMed ID: 33944714
    [No Abstract]   [Full Text] [Related]  

  • 24. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000955. PubMed ID: 10796397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refractory Raynaud's phenomenon in scleroderma: an indication for surgery.
    Wright HR; Drake DB; Gear AJ; Stiles BM; Edlich RF
    Am J Emerg Med; 1997 May; 15(3):328-30. PubMed ID: 9149005
    [No Abstract]   [Full Text] [Related]  

  • 27. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.
    Mikhailidis DP; Hutton RA; Jeremy JY; Dandona P
    Br Med J (Clin Res Ed); 1986 May; 292(6533):1461. PubMed ID: 3087473
    [No Abstract]   [Full Text] [Related]  

  • 28. Increased plasma adrenomedullin concentrations in patients with Raynaud's phenomenon.
    Letizia C; Danese C; D'Erasmo E
    J Rheumatol; 1999 Mar; 26(3):759-60. PubMed ID: 10090204
    [No Abstract]   [Full Text] [Related]  

  • 29. [Analysis of Raynaud's phenomenon in systemic scleroderma: comparative study with that in vibration disease].
    Maeda M; Shikano Y; Mori S
    Nihon Hifuka Gakkai Zasshi; 1989 Nov; 99(12):1255-9. PubMed ID: 2622060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynauds syndrome.
    Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD
    Prostaglandins Leukot Med; 1985 Jan; 17(1):1-9. PubMed ID: 3883365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases.
    Priollet P; Vayssairat M; Housset E
    Am J Med; 1987 Sep; 83(3):494-8. PubMed ID: 3661586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Points to consider-Raynaud's phenomenon in systemic sclerosis.
    Cutolo M; Smith V; Furst DE; Khanna D; Herrick AL
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v45-v48. PubMed ID: 28992170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma catecholamines during behavioral treatments for Raynaud's disease.
    Freedman RR; Keegan D; Migály P; Galloway MP; Mayes M
    Psychosom Med; 1991; 53(4):433-9. PubMed ID: 1924655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute estrogen administration can reverse cold-induced coronary Raynaud's phenomenon in systemic sclerosis.
    Lekakis J; Mavrikakis M; Emmanuel M; Prassopoulos V; Papamichael C; Moulopoulou D; Ziaga A; Kostamis P; Moulopoulos S
    Clin Exp Rheumatol; 1996; 14(4):421-4. PubMed ID: 8871843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Scleroderma and Raynaud's phenomenon: current pathogenetic interpretations and clinico-therapeutic trends].
    Zelli GP; Cannata P
    Ann Ital Chir; 1981; 53(3):337-43. PubMed ID: 7337317
    [No Abstract]   [Full Text] [Related]  

  • 37. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
    Gore J; Silver R
    Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
    [No Abstract]   [Full Text] [Related]  

  • 39. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raynaud's phenomenon and peripheral gangrene complicating scleroderma in pregnancy--diagnosis and management.
    Avrech OM; Golan A; Pansky M; Langer R; Caspi E
    Br J Obstet Gynaecol; 1992 Oct; 99(10):850-1. PubMed ID: 1419998
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.